Multiple outlets report on a single case in which a woman with advanced Alzheimer’s disease shows notable improvements after taking psilocybin, the active compound in “magic mushrooms.” According to the reports, her symptoms—described as including impaired speech and memory—improve following treatment. The coverage attributes the change to psilocybin and presents the account as a case report rather than evidence from large-scale clinical trials. The articles do not describe the woman’s age, the full treatment protocol, or details of how improvements are measured and compared over time, and they do not provide information on whether other therapies were used concurrently. While the reports emphasize the magnitude of the observed changes, they also frame the findings as limited to one individual. As a result, the reports do not establish that psilocybin is effective for Alzheimer’s in general, nor do they quantify how long any benefits last or what risks may apply.